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Increased Linear Bone Growth by
GH in the Absence of SOCS2 Is
Independent of IGF-1
ROSS DOBIE,1 SYED F. AHMED,2 KATHERINE A. STAINES,1 CHLOE PASS,1 SEEMA JASIM,1
VICKY E. MACRAE,1 AND COLIN FARQUHARSON1*
1The Roslin Institute and R(D)SVS, University of Edinburgh, Easter Bush, Midlothian, UK
2Developmental Endocrinology Research Group, School of Medicine, University of Glasgow, Yorkhill, Glasgow, Scotland, UK
Growth hormone (GH) signaling is essential for postnatal linear bone growth, but the relative importance of GHs actions on the liver and/
or growth plate cartilage remains unclear. The importance of liver derived insulin like-growth factor-1 (IGF-1) for endochondral growth
has recently been challenged. Here, we investigate linear growth in Suppressor of Cytokine Signaling-2 (SOCS2) knockout mice, which
have enhanced growth despite normal systemicGH/IGF-1 levels.Wild-type embryonic ex vivometatarsals failed to exhibit increased linear
growth in response to GH, but displayed increased Socs2 transcript levels (P< 0.01). In the absence of SOCS2, GH treatment enhanced
metatarsal linear growth over a 12 day period. Despite this increase, IGF-1 transcript and protein levels were not increased in response to
GH. In accordance with these data, IGF-1 levels were unchanged in GH-challenged postnatal Socs2-/- conditioned medium despite
metatarsals showing enhanced linear growth. Growth-plate Igf1 mRNA levels were not elevated in juvenile Socs2-/-mice. GH did however
elevate IGF-binding protein 3 levels in conditioned medium from GH challenged metatarsals and this was more apparent in Socs2-/-
metatarsals. GH did not enhance the growth of Socs2-/- metatarsals when the IGF receptor was inhibited, suggesting that IGF receptor
mediated mechanisms are required. IGF-2 may be responsible as IGF-2 promoted metatarsal growth and Igf2 expression was elevated in
Socs2-/- (but notWT)metatarsals in response toGH. These studies emphasise the critical importance of SOCS2 in regulating GHs ability to
promote bone growth. Also, GH appears to act directly on the metatarsals of Socs2-/- mice, promoting growth via a mechanism that is
independent of IGF-1.
J. Cell. Physiol. 230: 2796–2806, 2015. © 2015 The Authors. Journal of Cellular Physiology Published by Wiley Periodicals, Inc.
The anabolic role of growth hormone (GH) in long bones is
well accepted. The relative contributions of GH acting on the
liver (increasing growth promoting endocrine factors) or
directly (on growth plate cartilage) however remain unclear
(Lupu et al., 2001). It is likely that both these modes of GH
action function in a highly coordinated manner to regulate
growth plate function and linear bone growth. GH increases
insulin like growth factor-1 (IGF-1) production in a number of
tissues. Speciﬁcally, GH acting on the liver results in an increase
in circulating IGF-1 which functions in an endocrine manner
(Sjogren et al., 1999; Yakar et al., 1999). GH induced IGF-1
production within the growth plate cartilage functions in an
autocrine/paracrine manner. Furthermore, GHmay also act on
the growth plate via IGF-1 independent mechanisms (Gevers
et al., 2002a; Wang et al., 2004).
As expected, studies with Snell (dw/dw) and Ames (df/df)
hypopituitary dwarf mice reveal a reduction in body weight and
growth retardation. Mice with global inactivated GHR (ghr),
GH- releasing hormone receptor (ghrhr), IGF-1 (Igf1), IGF-1
receptor (IGF-1R; Igf1r), and insulin receptor substrate-1 (Irs-1)
have a similar phenotype (Sinha et al., 1975; Smeets and
Vanbuuloffers, 1983a,b; Li et al., 1990; Sornson et al., 1996;
Wang et al., 2004).
The importance of circulating IGF-1 on linear growth was
challenged by two independent studies. Liver-speciﬁc IGF-1
deﬁcient (LID) mice have a signiﬁcant reduction of circulating
IGF-1, but body weight and bone length were essentially
normal (Sjogren et al., 1999; Yakar et al., 1999). Furthermore, a
phenotypic comparison of LID, acid labile subunit knockout
(ALSKO), insulin like growth factor binding protein (IGFBP)-3
knockout (BP3KO), and triply deﬁcient LID/ALSKO/BP3KO
mice indicated that while all had decreased serum IGF-1 levels
this did not predict linear growth potential (Yakar et al., 2009).
Compared toWTmice, ALSKOmice (60% reduction in serum
IGF-1) were 8% shorter, whereas BP3KOmice (40% reduction
in serum IGF-1) were 5% longer, and LID mice (80% reduction
in serum IGF-1) were of equal length. Most strikingly, despite
virtually undetectable circulating IGF-1 (2.5% of WT IGF-1
levels), the triply deﬁcient LID/ALSKO/BP3KO mice exhibited
only a modest 6% decrease in body length, comparable to that
of the ALSKO mice that had much greater serum IGF-1 levels
(Yakar et al., 2009). However, interpretation of some of these
observations is complicated by a marked increase in circulating
GH to supraphysiological levels (Yakar et al., 2002) and models
with a physiological level of circulating GH maybe more
informative.
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Some function has been attributed to circulating IGF-1, and it
is possible that a threshold concentration of circulating IGF-1 is
required for normal linear growth (Lupu et al., 2001). The data
from the LID/ALSKO/BP3KO mice however are at odds with
this concept (Yakar et al., 2002; Yakar et al., 2009). When
hepatic IGF-1 production was achieved in mice lacking Igf1
gene expression in all other tissues, it was found that circulating
IGF-1 contributes to 30% of the adult body size and sustains
postnatal development (Stratikopoulos et al., 2008). Similarly,
in Igf1 null mice with hepatic over expression of the rat Igf1,
serum IGF-1 production supported normal body growth
during and after puberty, despite absence of tissue IGF-1 (Wu
et al., 2009; Elis et al., 2010).
Alternative strategies to delineate between circulating and
local IGF-1 effects on linear bone growth have involved the
targeted deletion of Igf1 in epiphyseal chondrocytes. Thesemice
had a 40% reduction in cartilage IGF-1 expression and normal
circulating IGF-1 levels (Govoni et al., 2007). Linear growth was
reduced by 27% between 2 and 4 weeks of age, highlighting that
local chondrocyte-produced IGF-1 is an important regulator of
longitudinal growth. While highly informative, these studies fail
to address the possibility of a GH action on the growth plate,
which is independent of IGF-1. Double ghr/igf1 KO mice have a
more severe phenotype than ghr or igf1 KO’s alone suggesting
that there are GH actions on linear bone growth that are
independent of IGF-1 (Lupu et al., 2001).
A role for GH acting directly on growth plate cartilage is also
suggested by data from suppressor of cytokine signaling 2
(SOCS2) null mice (Metcalf et al., 2000; MacRae et al., 2009).
SOCS2 is expressed by epiphyseal chondrocytes, and is a
recognised negative regulator of GH signaling via inhibition of
the Janus kinase/signal transducers and activators of
transcription (JAK/STAT) pathway (Hilton, 1999; Greenhalgh
et al., 2002; Rico-Bautista et al., 2006; Flores-Morales et al.,
2006; Pass et al., 2009). Intriguingly, these mice are
characterized by increased growth, including increased long
bone length and mass, without elevated circulating levels of
IGF-1 or GH (Metcalf et al., 2000; Greenhalgh et al., 2005;
MacRae et al., 2009; Dobie et al., 2014). It can therefore be
assumed that GH actions directly on growth plate cartilage
(IGF-1 dependent or independent) are driving this increased
linear bone growth.
The ex vivo metatarsal culture method has been exploited in
many studies as a method for analysing endochondral bone
growth. This model provides a more physiological environment
than cultured chondrocytes as chondrocyte interactions with
each other and the extracellular matrix (ECM) are maintained.
(Mushtaq et al., 2004; MacRae et al 2007; Chagin et al 2010).
Studies have shown that the growth rate of embryonic bones in
culture is similar to that found in vivo (Scheven&Hamilton 1991;
Coxam et al., 1996). Furthermore, the ability to grow
metatarsals in long-term cultures without fetal bovine serum
allows for the manipulation of medium conditions and
investigation of the effects of various treatments. Recently, it has
been reported that GH is able to stimulate longitudinal growth
of Socs2-/-metatarsals, but notWTbones (Pass et al., 2012). The
Socs2-/-metatarsal culturemodel is therefore a valuablemodel in
investigating the mechanisms by which local GH enhances linear
bone growth.
This study aimed to utilize themetatarsal organ culturemodel
to explore the mechanisms by which linear bone growth is
enhanced in Socs2-/- mice, and in doing so, establish the
mechanisms of GH’s control of growth plate function.
Materials and Methods
Mice
Socs2-/- mice were generated as previously described (MacRae
et al., 2009). For genotyping, tail or ear biopsiedDNAwas analyzed
by PCR for SOCS2 (WT) or the neocassette (Socs2-/-) Primer
sequences can be found in Supp. Table S1 (EuroﬁnsMWGOperon,
London, UK) (Pass et al., 2012). All animal experiments were
approved by Roslin Institute’s Animal Users Committee, and the
animals were maintained in accordance with Home Ofﬁce (UK)
guidelines for the care and use of laboratory animals.
Growth analysis and growth plate dynamics
Six-week-old male WT and Socs2-/- mice received a subcutaneous
injection of 10mg/kg calcein (Sigma, Poole, UK) in sodium
bicarbonate solution 2 days prior to sacriﬁce. Tibiae, ﬁxed
overnight in 4% paraformaldehyde (PFA) were embedded in
methylmethacrylate and sections (5mm) were cut and processed
using standard procedures (Idris et al., 2009). The longitudinal
bone growth rate was measured as previously described (Owen et
al 2009; Pass et al., 2012). In brief, the distance between the original
growth plate mineralization front and the ﬁnal ﬂuorescing
mineralization front within the metaphysis was measured at 10
different points along the width of the section using image analysis
software and a Leica DMBR ﬂuorescent microscope.
Measurements were divided by the number of days between
injection and sacriﬁce (2 days) to give a bone formation rate per
day. Four sections per tibia were measured from 6mice per group.
Embryonic and postnatal metatarsal organ culture
The middle three metatarsals were isolated from 17-day-old WT
and Socs2-/- embryos (E17) or 3-day-old (PN3) WT and Socs2-/-
pups. At both developmental ages the growth plate contains both
proliferating and hypertrophic chondrocytes but the primary
ossiﬁcation center, while newly formed in E17 metatarsals, is
almost completely developed in PN3 bones (van Loon et al 1995;
Reno et al., 2006). Each bone was cultured individually in 1 well of a
24-well plate (Costar, High Wycombe, UK) in 300ml aMEM
medium (without ribonucleosides) or 300ml DMEMþ F12
medium supplemented with 0.2% BSA (Fraction V), 5mg/ml
L-ascorbic acid phosphate, 1mM b-glycerophosphate, 0.05mg/ml
gentamicin, 1.25mg/ml fungizone (Invitrogen, Paisley, UK) as
previously described (Chagin et al., 2010; Pass et al., 2012). The
perichondrium and the primary ossiﬁcation center was not
removed prior to explant culture. Recombinant human (rh)GH
and rhIGF-1 (Bachem, Merseyside, UK; both 100 ng/ml) were
added as used previously (Mushtaq et al., 2004a; MacRae et al.,
2006a; Pass et al., 2012). Recombinant mouse (rm)IGF-2 (R&D
systems, Minneapolis, MN) was added at the same concentration
as rhIGF-1 (100 ng/ml). One micrometer NVP-AEW541 (IGF-1
receptor kinase inhibitor) (Garcia-Echeverria et al., 2004; Gan
et al., 2010) was added 16 h prior to the addition of GH. Bones
were incubated in a humidiﬁed atmosphere (37°C, 5%CO2), for up
to 13 days. Bone lengths were measured from articular surface to
articular surface through the middle of the metatarsals using a
Nikon eclipse TE300 microscope with a digital camera attached,
using Image Tool (Image Tool Version 3.00, San Antonio, TX). For
RNA extraction 3–4 bones were pooled in 100ml Trizol reagent
(Invitrogen) at days 7 and 12 of culture and RNA extracted
according to the manufacturer’s instructions (RNeasy Mini Kit,
Qiagen). Conditioned medium was collected at days 5, 7, and 12
and stored at 80°C.
Growth plate micro dissection and RNA extraction
Tibiae were dissected from 7-week-old male WT (n¼ 4) and
Socs2-/- mice (n¼ 3). Bones were brieﬂy immersed in 4% aqueous
(wt./vol.) polyvinylalcohol (PVA; Grade GO4/140, Wacker
Chemicals, Walton-on-Thames, UK), chilled by precipitate
immersion in n-hexane (BDH, Poole, UK; grade low in aromatic
hydrocarbons) and stored at80°C (25;26). Using optimal cutting
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temperature (OCT) embedding medium (Brights, Huntingdon,
UK), 30mm thick longitudinal sections of the proximal tibia were
cut at 30°C (Brights, OT model cryostat), mounted on
Superfrost Plus slides (Fischer Scientiﬁc, Chicago, IL) before
storage at 80°C. Slides were brieﬂy thawed as described
previously (Nilsson et al., 2007; Staines et al., 2012), and then
dehydrated in graded solutions of ethanol (70%, 95%, and 100%)
with sections kept under a xylene droplet throughout the
microdissection. The entire growth plate was dissected free from
the perichondrium, the secondary ossiﬁcation zone and the
primary spongiosa. Growth plates from both tibae of each mouse
were pooled in 2.88ml b-mercaptoethanol (Sigma, Poole, Dorset)
and 400ml Solution C (0.322 g guanidine thiocyanate, 377ml
nuclease free water, 23ml 0.75M sodium citrate). From each
animal approximately 40–60mg of growth plate tissue was
obtained and RNA isolation was performed using proeteinase K
digestion followed by phenol:chloroform extraction as previously
described (Heinrichs et al., 1994).
Real-time quantitative PCR (RT-qPCR)
RNA content was assessed using a nanodrop spectrophotometer
(Thermo Scientiﬁc, Chicago, IL) by the absorbance at 260 nm and
purity by A260/A280 ratio. Reverse-transcription was completed
as described previously (Farquharson et al., 1999; Houston et al.,
1999). RT-qPCR was performed using the SYBR green (Roche)
detection method on a Stratagene Mx3000P real-time qPCR
system (Stratagene, CA) using the following programme: 1 cycle at
95°C for 15min; 40 cycles at 94°C for 15 sec; 55°C for 30 sec;
72°C for 30 sec; 1 cycle at 95°C for 1min, 55°C for 30 sec and
95°C for 30 sec. Relative gene expression was calculated using the
DDCt method (Livak and Schmittgen, 2001). Each cDNA sample
was normalized to housekeeping gene gapdh (Primer Design,
Southampton, UK) as previously described (Martensson et al
2004). Reactions were performed with gene of interest primers
Igf1,Igfbp3, and Igf2 (Invitrogen), as well as Socs1, Socs2, and Socs3
(Supp. Table 1).
Immunohistochemistry
Tibiae were dissected from 6-week-old male WT (n¼ 6) and
Socs2-/- mice (n¼ 6) and ﬁxed in 70% ethanol for 48 h at 4°C
before decalciﬁcation in 10% EDTA (pH 7.4) for approximately
4 weeks at 4°C with regular changes. Tissues were ﬁnally
dehydrated and embedded in parafﬁn wax, using standard
procedures, and sectioned at 5mm. For immunohistochemical
analysis, sections were dewaxed in xylene and rehydrated before
incubation at 37°C for 30min in 0.1% trypsin (Sigma) for antigen
demasking. Endogenous peroxidases were blocked by 0.03%
H2O2 in methanol (Sigma) for 30min. Antibodies to IGFBP3 and
IGF-2 (both Santa Cruz Biotechnology, Heidelberg, Germany)
were diluted to 0.4mg IgG/ml and 0.5mg IgG/ml, respectively and
incubated for 18 h at 4°C. Control sections were incubated with
an equal concentration IgG. A Vectastain Rabbit ABC kit (Vector
Laboratories, Peterborough) was then used according to the
manufacturer’s instructions. The sections were ﬁnally
dehydrated, counterstained with hematoxylin and mounted in
DePeX.
Conditioned medium analysis
Total IGF-1 and IGFBP3 levels in conditioned medium from
metatarsals culturedGH were assessed at days 5, 7, and 12 by
ELISA (Quantikine, R&D Systems, Minneapolis, MN). IGF-2 levels
in conditioned medium were assessed at day 12 (Ray Biotech, Inc)
according to the manufacturer’s instructions. IGF-1 assays
included a step to dissociate the potentially interfering binding
proteins from the ligand.
Statistical analysis
Direct comparison between two sets of data was done by
Student’s t-test or a suitable non-parametric test if the data was
not normally distributed. Time course experiments were analyzed
with a repeated measures 2-way ANOVA for which suitable
post-tests for multiple comparisons were conducted. Analysis was
carried out using SigmaPlot v11.0 (Systat Software Inc, London,
UK). Data are presented as mean standard error of the mean
(SEM). P values <0.05 were considered signiﬁcant.
Results
SOCS2 regulation of GH induced growth in metatarsals
WT metatarsals extracted at E17 did not increase their length
in response to GH over the 12 day culture period (Fig. 1A).
Transcript analysis at day 7, revealed a 17-fold increase in Socs2
mRNA expression in the GH-treated group in comparison to
the control group (P< 0.01) (Fig. 1B). Socs1 and Socs3 mRNA
expressions were however not enhanced in response to GH
(Fig. 1B). Socs2-/- metatarsals growth signiﬁcantly increased in
response to GH from day 7 to day 12 (P< 0.05) (Fig. 1C),
similar to previous studies (Pass et al., 2012). IGF-1 stimulated
longitudinal growth inWT and Socs2-/-metatarsals as expected.
The level of stimulation in the presence of IGF-1 was
comparable between WT and Socs2-/- metatarsals, indicating
that SOCS2 does not regulate IGF-1 induced growth in this
model (Fig. 1A and C). Assessment of WT and Socs2-/- PN3
metatarsals revealed a similar GH response to that noted with
the embryonic metatarsal with only the Socs2-/- bones showing
enhanced growth in response to GH (P< 0.01) (Supp. Fig. 1A
and C). Also, Socs2 but not Socs1 or 3 mRNA expression was
increased in response to 12 days of GH treatment (4-fold;
P< 0.01) in WT metatarsals (Supp. Fig. 1B). Taken together,
these data indicate that SOCS2 is a major regulator of GH
promotion of longitudinal growth in the metatarsal organ
culture model.
Increased growth of Socs2-/- metatarsals in response to
GH is not associated with an increase in chondrocyte
IGF-1
Wenext aimed to determine if the growth promoting effects of
GH on Socs2-/- metatarsals were direct or mediated by IGFs.
Following 7 days of GH treatment, WTmetatarsals showed no
increase in longitudinal growth compared to untreated
samples, whereas Socs2-/- metatarsal growth increased by 15%
(P< 0.01) (Fig. 2A and B). Expression levels of Igf1, Igfbp3, and
Igf2 at this time point were unaltered in response to GH inWT
and Socs2-/- metatarsals (Fig. 2C). Protein analysis of day 5
conditioned medium revealed increased IGFBP3 protein levels
in GH-treated Socs2-/- (Control 8.2 1.35, GH 23.5 5.76;
P< 0.01), but not in corresponding WT conditioned medium
(Tables 1 and 2). ELISA analysis of day 7 conditioned medium
similarly found no increase in IGF-1 or IGFBP3 protein levels in
GH treated WT metatarsals (Table 1). While IGF-1 remained
at basal level in GH-stimulated Socs2-/- conditioned medium at
day 7, IGFBP3 levels increased signiﬁcantly (Control 5.2 0.94,
GH 22.6 3.34; P< 0.01) (Table 2).
At day 12, Socs2-/- metatarsal growth increased by 23%
(P< 0.01) in response to GH, while WT metatarsal growth
remained at control level (Fig. 2A and B). Similar to the day 7
data; expression levels of Igf1, Igfbp3, and Igf2 were unaltered in
response to GH in WT metatarsal (Fig. 2D). Similarly, Igf1
transcript levels remained at basal level in GH-treated Socs2-/-
metatarsals, whereas Igfbp3 and Igf2 transcript levels
signiﬁcantly increased by 3.5- (P< 0.05) and 4.6- fold (P< 0.05)
respectively (Fig. 2D). A similar trend was observed when
analyzing protein levels of conditioned medium (Tables 1 and
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2). GH failed to have a stimulatory effect on IGF-1 levels inWT
or Socs2-/- conditioned medium. However, GH treatment did
result in a 59% (P< 0.01) and 123% (P< 0.001) increase in
IGFBP3 levels in WT and Socs2-/- conditioned medium,
respectively. IGF-2 protein levels were also increased in Socs2-/-
conditioned medium in response to GH (P< 0.001) (Table 2).
No increase in IGF-2 levels was observed in correspondingWT
medium (Table 1).
Experiments carried out on PN3 metatarsals produced
comparable results to those observed in E17 metatarsals in
terms of IGF-1 production. Despite there being an increase in
growth of Socs2-/- metatarsals in response to GH, IGF-1 levels
in conditioned medium at day 7 and 12 were not preferentially
increased in Socs2-/- metatarsals (Supp. Tables 2 and 3). GH
stimulated IGFBP3 protein levels in WT-conditioned medium,
an increase that appeared to be enhanced in the absence of
SOCS2 at day 12 (Supp. Tables 2 and 3). A comparable increase
in IGF-2 levels in conditioned medium following GH treatment
was observed in WT and Socs2-/- metatarsals (Supp. Tables 2
and 3).
These data reveal that increased longitudinal growth in
response to GH observed in the Socs2-/- metatarsal model is
not mediated by increased IGF-1 expression. They also
highlight the possible importance of IGFBP3 and IGF-2 in this
model as secondary messengers to GH in promoting
longitudinal bone growth in Socs2-/- metatarsals.
Altered IGF-2 and IGFBP3 levels in the growth plates of
Socs2-/- mice
Examination of growth plates fromWTmice indicated that both
IGF-2 and IGFBP3 protein were preferentially localized to the
proliferating zone of the growth plate with little or no staining in
the hypertrophic chondrocytes. The staining in the proliferating
chondrocytes of the Socs2-/- growth plates of both IGF-2 and
IGFBP3 appeared similar to that observed in similarly stained
WT growth plates. In contrast, growth plates from Socs2-/-mice
contained a greater number of hypertrophic chondrocytes that
stained positively for both IGF-2 and IGFBP3 (Fig. 3). All control
sections showed no staining (data not shown).
Fig. 1. SOCS2 regulation of GH-induced embryonic metatarsal growth. Graphs showing (A) WT and (C) Socs2-/- E17 metatarsal growth in
response to GH or IGF-1 (100ng/ml) over a 12 day period. Data are presented as meanSEM. Significance denoted by IGF-1 versus control
aP< 0.05, bP< 0.001. GH versus control cP< 0.05, dP< 0.001, (n 6). (B) Transcript analysis of Socs1, 2, and 3 in WT metatarsals following
7 days GH (100ng/ml) treatment. Data represented as meansSEM. Significance from untreated metatarsals denoted by aP< 0.05, b P< 0.01,
(n¼ 3).
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No additive effects of GH and IGF-1 action in the
promotion of metatarsal linear growth
Having shown that both GH and IGF-1 stimulated longitudinal
growth in Socs2-/- metatarsals, and that GH stimulation was
independent of increased IGF-1 levels, we next aimed to
determine if the actions of GH and IGF-1 on longitudinal
growth were additive. Dual treatment with GH and IGF-1 in
WT metatarsals signiﬁcantly increased growth in comparison
to control samples (P< 0.001) (Fig. 4A). This level of increase
did not differ from that observed with IGF-1 treatment alone.
In Socs2-/- metatarsals, growth was signiﬁcantly increased in
response to both IGF-1 and GH treatment in comparison to
control samples (P< 0.01, P< 0.05 respectively; Fig. 4B). There
was no additional increase in metatarsal growth upon dual
treatment (Fig. 4B).
The IGF-1R is critical for GH-induced growth
The cellular responses of IGF-1 and IGF-2 are both mediated
through the IGF-1R. To investigate the importance of this
Fig. 2. Igf1, Igfbp3, and Igf2 transcript analysis following GH treatment. Graphs showing (A) WT and (B) Socs2-/- E17 metatarsal growth in
response to GH (100ng/ml) over a 12 period. Dotted lines represent points at which Igf1, Igfbp3, and Igf2 expression levels were measured.
Data are presented as meanSEM. Significance from untreated metatarsals denoted by aP< 0.05, bP< 0.01 (n 6). Transcript analysis of Igf1,
Igfbp3, and Igf2 in WT and Socs2-/- metatarsals following (C)7- and (D)12 days GH (100ng/ml) treatment. Data are presented as meanSEM.
Significance from untreated metatarsals denoted by aP< 0.05, (n¼ 3)
TABLE 1. IGF-1, IGFBP3, and IGF-2 protein levels in conditioned medium from E17 WT metatarsals following 5, 7, or 12 days GH (100 ng/ml) treatment.
Day Treatment IGF-1 (ng/ml) IGFBP3 (ng/ml) IGF-2 (ng/ml)
5 Control 2.4 0.48 9.0 1.43 nd
GH 2.1 0.23 9.7 1.41 nd
7 Control 6.4 0.86 12.2 1.68 nd
GH 4.0 0.70 19.7 4.57 nd
12 Control 11.6 1.16 25.0 5.09 7.0 1.39
GH 9.5 1.06 39.8 3.69a 8.4 0.97
Data are presented as mean SEM (n 5). Signiﬁcance from day matched control samples denoted by aP< 0.05. nd¼ no data.
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receptor in mediating the effects of GH on longitudinal bone
growth, we assessed the growth of Socs2-/- metatarsals in the
presence of GH and an IGF-1R inhibitor (NVP-AEW541).
Initially, WT metatarsals were treated with varying
concentrations of NVP-AEW541 for 5 days before the
inhibitor was removed from the medium (Fig. 4C). All
concentrations of NVP-AEW541 (1–4mM) inhibited
metatarsal growth conﬁrming that endogenous IGF signaling is
important for metatarsal growth. One micrometer of
NVP-AEW541 was selected for future experiments as on the
removal of the inhibitor, metatarsals showed increased growth
suggesting that the inhibitor at this concentration (cf 3 and
4mM) had no lasting toxic effects on growth potential. Socs2-/-
metatarsals treated with the NVP-AEW541 showed
signiﬁcantly decreased growth compared to control samples
(P< 0.05, Fig. 4D). GH treatment was unable to stimulate
growth in the presence of the IGF-1R inhibitor, suggesting that
the effects of GH on longitudinal bone growth are mediated
through the IGF-1R.
IGF-2 stimulation of embryonic Socs2-/- metatarsals
As GH-induced growth in Socs2-/- metatarsals was associated
with an increase in IGF-2 levels (Table 2), we next determined if
IGF-2 could stimulate longitudinal growth. IGF-2 treatment
signiﬁcantly increased longitudinal growth of Socs2-/-
metatarsals from day 5 to 12 (P< 0.05; Fig. 4E). This enhanced
growth by IGF-2 was however, signiﬁcantly less than that
stimulated by equimolar IGF-1, indicating that IGF-1 is the
more potent of the two IGF ligands in promoting linear bone
growth (Fig. 4E). Similar results were observed in WT
metatarsals (data not shown).
Igf1 mRNA levels in the Socs2-/- growth plate
Calcein labeling of 6-week-old Socs2-/- mice revealed that tibial
growth over a 2 day period of Socs2-/-mice (44.5 1.8mm) was
increased in comparison to WT mice (36.8 1.57mm) (21%;
p<0.05) (Fig. 5A). Igf1 levels were also assessed in the growth
plates of WT and Socs2-/- mice and found not to be signiﬁcantly
altered from expression levels ofWT mice. Therefore, despite
increased bone growth rates in Socs2-/- mice there was no
elevation in growth plate Igf1 transcript levels (Fig. 5B).
Discussion
It is widely understood that GH action on growth plate
chondrocytes is an important regulator of linear growth
(Ahmed and Farquharson, 2010). The intimate relationship
between GH and IGF-1 does however make it difﬁcult to
attribute speciﬁc actions to GH, or those resulting through
IGF-1. Tibial growth is reduced in both ghr and Igf1 null mice.
This reduction in growth becomes more severe in the double
ghr/igf1 mutants, suggesting that GH and IGF-1 have
independent functions (Lupu et al., 2001). In agreement with
this, mice deﬁcient of GH show a much higher reduction in
longitudinal bone growth than Igf1 null mice (Sims et al., 2000;
Mohan et al., 2003; Wang et al., 2004). The present study
demonstrates that despite no elevation in IGF-1 gene and
protein expression levels in Socs2-/- metatarsals following GH
treatment, GH enhances linear bone growth. This indicates
that the growth promoting effects of GH are not accompanied
by a rise in IGF-1 expression by chondrocytes or cells of the
perichondrium, which previous studies have indicated is a
major source of Igf1 in the growing bone (Parker et al., 2007).
This was supported by the observation of normal Igf1
expression levels in the growth plates of Socs2-/- tibia which are
characterized by wider growth plates and longer bones
(MacRae et al., 2009; Pass et al., 2012).
In addition to their normal GH and IGF-1 serum
concentrations, Socs2-/- mice also have normal carbohydrate
metabolism compared with ALSKO, BP3KO, LID, and IGF-1
null mice (Rico-Bautista et al., 2005; Yakar et al., 2009). Thus,
the Socs2-/- mouse may represent an important model to study
local autocrine/paracrine pathways that promote linear bone
growth without leading to insulin resistance and altered
carbohydrate metabolism.
Several studies have used the fetal mouse metatarsal culture
methods to investigate the anabolic effects of IGF-1 on linear
bone growth. Increased growth of metatarsals in response to
IGF-1 is coupled with an increase in proliferation and an
increase in hypertrophic zone size (Mushtaq et al., 2004;
MacRae et al., 2006, 2007; Chagin et al., 2010). The effects of
TABLE 2. IGF-1, IGFBP3, and IGF-2 protein levels in conditioned medium from E17 Socs2-/- metatarsals following 5, 7, or 12 days GH (100 ng/ml) treatment
Day Treatment IGF-1 (ng/ml) IGFBP3 (ng/ml) IGF-2 (ng/ml)
5 Control 2.7 0.59 8.2 1.35 nd
GH 2.6 0.26 23.5 5.76b nd
7 Control 3.3 0.39 5.2 0.94 nd
GH 2.8 0.28 22.6 3.34b nd
12 Control 9.9 0.90 22.2 3.51 1.7 0.34
GH 7.0 0.39 49.6 1.89c 17.1 1.72c
Data are presented as mean SEM (n 5). Signiﬁcance from control day matched control samples denoted by bP< 0.01, cP< 0.001.
Fig. 3. Immunohistochemical localization of IGF-2 and IGFBP3 to
the proliferating and hypertrophic chondrocytes of WT and Socs2-/-
growth plates. In contrast to WT growth plates, hypertrophic
chondrocytes within the Socs2-/- growth plate expressed high levels
of both IGF-2 and IGFBP3 (arrows). Scale bars¼ 50mm
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Fig. 4. Effect of IGF-1R inhibitor, IGF-2, and combined IGF-IþGH on metatarsal growth. Graphs showing (A) WT and (B) Socs2-/- E17
metatarsal growth in response to GH or IGF-1 (100ng/ml) or GHþ IGF-1 over a 13–14 day period. Data are presented as meanSEM.
Significance denoted by GH versus control aP< 0.05, bP< 0.001. IGF-1 versus control cP< 0.05, dP< 0.01, e P< 0.001, GHþIGF-1 versus control
fP< 0.05, gP< 0.01, hP< 0.001, (n 6). (C) Graph showing WT E17 metatarsal growth in response to NVP-AEW481 (1–4mM) for 5 days with
4 days recovery. Data are presented as meanSEM. (n 6). (D) Graph showing Socs2-/- E17 metatarsal growth in response to GH (100ng/ml),
NVP-AEW481 (1mM) or GHþNVP-AEW481. Data are presented as meanSEM. Significance of GH versus control denoted by aP< 0.05,
bP< 0.01, (n 6). (E) Graph showing Socs2-/- E17 metatarsal growth in response to IGF-1 or IGF-2 (100ng/ml). Data are presented as
meanSEM. Significance denoted by IGF-1 versus control aP< 0.01, bP< 0.001. IGF-2 versus control cP< 0.05 dP< 0.01, (n 6).
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GH on metatarsal growth are however less clear, with GH
being shown to either stimulate or have no effect on growth
(Scheven and Hamilton, 1991; Mushtaq et al., 2004; Pass et al.,
2012). In chondrocytes, GH is able to stimulate SOCS2
expression (Pass et al., 2012) and we have now further shown
that SOCS2 is a negative regulator of GH’s capability to
promote longitudinal bone growth in the metatarsal organ
culture model. This observation is in agreement with previous
reports where mice missing the Socs2 gene have increased
linear bone growth due to increased signaling through theGHR
(Metcalf et al., 2000; Greenhalgh et al., 2005; MacRae et al.,
2009). Although, it is well recognized that GH signaling is also
modulated by CIS and SOCS1 and 3 we have reported
previously that GH does not stimulate chondrocyte SOCS 1 or
3 protein levels (Pass et al., 2009, 2012). Furthermore, Socs1-/-
and Socs3-/- mice are perinatal and embryonic lethal,
respectively and little data exists on their ability to regulate
bone growth (Greenhalgh and Alexander, 2004).While further
studies are required to investigate GH ability to stimulate
chondrocyte CIS expression it is of interest to note that Cis-/-
mice exhibit no obvious growth phenotype (Greenhalgh and
Alexander, 2004).
It is widely established that the prenatal growth promoting
effects of IGF-1 are GH independent, and that GH has little or
no role in promoting growth in embryonic development
(Waters and Kaye, 2002). Therefore, these key studies were
also completed using postnatal metatarsals, which may be
more sensitive to the growth promoting actions of GH. No
evidence for this was however observed in our experiments
and older postnatal bones may have to be studied to see a GH
response. However, this was not possible as our pilot studies
(data not shown) indicated that 3-day-old postnatal metatarsals
was the oldest age we could study to get measurable growth.
Even at postnatal day 3, bone growth was much less than
embryonic metatarsals and this is in accord with previous
observations (Macrae et al. and 2006; Chagin et al., 2010). It is
therefore tantalizing to speculate that variable SOCS2
expression in normal animals may “ﬁne tune” the chondrocytes
ability to respond to GH. Such a regulatory mechanism may
permit postnatal bones at a speciﬁc developmental age to
respond to GH and further studies are required to investigate
this.
Socs2-/- mice have increased linear bone growth consistent
with increased signaling through the GHR (Metcalf et al., 2000;
Fig. 5. Normal IGF-1 mRNA expression in Socs2-/- growth plate. (A) Analysis of longitudinal bone growth rate by dynamic
histomorphometry of 6-week-old male WT and Socs2-/- mice. The red lines indicate the distance between the original growth plate
mineralization front at the proximal end of the tibia and the fluorescing mineralization front. The numbers under the images indicate
longitudinal bone formation rate (mm/day). Scale bars¼ 100mm. Data presented as meanSEM. Significance denoted by aP< 0.05, (n 6).
(B) Transcript analysis of Igf1 expression in WT and Socs2-/- growth plates, micro-dissected from 7-week-old male mice. Data are presented as
fold change relative to WT expression as meanSEM, (n 3).
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Greenhalgh et al., 2005; Lorentzon et al., 2005; MacRae et al.,
2009; Pass et al., 2012). As Socs2-/- mice are devoid of higher
circulating IGF-1 levels, it is likely that the increased linear bone
growth and structural alterations within Socs2-/- growth plate
are a direct consequence of GH acting directly on growth plate
cartilage (Lorentzon et al., 2005; MacRae et al., 2009). The
broad distribution of both the GHR and IGF-1R within the
growth plate suggests GH/IGF-1may play a role in chondrocyte
proliferation, differentiation, and hypertrophy (Lupu et al.,
2001; Gevers et al., 2002b; Wang et al., 2011). The germinal
zone of the growth plates are signiﬁcantly enlarged in Igf1 null
mice, supporting the idea that GH stimulates longitudinal bone
growth independent of IGF-1 (by stimulating the differentiation
of growth plate precursor cells), and via an IGF-1 dependent
mechanism (by inducing Igf1 expression in differentiating
chondrocytes which then in-turn stimulate clonal expansion)
(Isaksson et al., 1987; Wang et al., 2004). Although IGF-1 is
expressed in all maturational growth plate zones, it is
understood to act mainly on the hypertrophic zone. Igf1-/-mice
have attenuation of chondrocyte hypertrophy with no changes
in proliferation (Wang et al., 1999). Addition of IGF-1 to
metatarsals leads to an increase in hypertrophic zone lengths as
well as increased size of individual chondrocytes (Mushtaq
et al., 2004). Thesemechanistic observations are important as a
large part of growth of cultured metatarsals is due to
hypertrophic differentiation but it is recognized these
observation may not translate directly to the in vivo situation
where matrix production, proliferation and hypertrophy all
contribute to linear bone growth (Wilsman et al., 1996).
The GH signaling mechanisms responsible for increasing
linear bone growth have been recently clariﬁed in studies
where GH was found to stimulate the phosphorylation of
STATs 1, 3, and 5 in chondrocyte cultures (Pass et al., 2012).
The activation of chondrocyte STAT signaling was both
increased and prolonged in chondrocytes from Socs2-/- mice in
comparison to cells from WT mice (Pass et al., 2012). This
explains the observed GH stimulation of linear growth of
Socs2-/- embryonic metatarsals and the proliferation of
chondrocytes within (Pass et al., 2012).
Both IGF-1 and IGF-2 are important regulators of skeletal
growth. While IGF-1 is important for both fetal and postnatal
growth, IGF-2 is thought to function only in the former.
IGF-2 is highly expressed in a variety of tissues in the embryo,
and is dramatically down-regulated shortly after birth (Lui
et al., 2008). Disruption of the Igf2 gene results in progeny
that are 60% smaller than WT littermates, however postnatal
growth is comparable to WT (Dechiara et al., 1990).
Although it is widely understood that IGF-2 actions are
independent of GH regulation, GH has been shown to
regulate IGF2 transcription in the human liver (von Horn
et al., 2002). In this present study, both during fetal and early
postnatal linear growth, IGF-2 levels are regulated by GH. It
is conceivable that the increase in linear growth observed in
Socs2-/- metatarsals are a result of elevated IGF-2 levels. IGF-2
can promote the expansion of fetal hypertrophic
chondrocytes in cultured limb explants, possibly through
activation of the PI3K and TGF-ß pathways and downstream
elevation of transcription factors (Hamamura et al., 2008;
Chen et al., 2010). Both IGF-1 and IGF-2 bind to the IGF-1R,
and the cellular responses of both ligands are mediated
through this receptor. As inhibition of this receptor
abrogates the growth promoting effects of GH, it stands to
reason that IGF’s are responsible for mediating the increase
in linear growth. As there is no increase in the expression of
IGF-1 in response to GH, it is possible that IGF-2 and not
IGF-1 is responsible for the GH promoted linear growth of
the Socs2-/- metatarsals. In agreement with this, IGF-2 was
able to stimulate longitudinal bone growth in metatarsals
from WT and Socs2-/- mice.
Conﬁrmation of increased expression of IGF-2 and IGFBP3
by the hypertrophic chondrocytes of growth plates in response
to unrestricted GH signaling was revealed by
immunohistochemical analysis of Socs2-/- growth plates. The
presence of IGF-2 and IGFBP3 in hypertrophic chondrocytes is
consistent with GHR expression in these cells of the growth
plate and our previous observation of increased numbers of
phosphorylated STAT-5–positive hypertrophic chondrocytes
of Socs2-/- growth plates (Gevers et al., 2002b; Pass et al., 2012).
The staining in the proliferating chondrocytes of the Socs2-/-
growth plates appeared similar to that observed in the WT
growth plates however it was not possible, because of the
nonquantitative nature of immunohistochemistry, to compare
levels of IGF-2 and IGFBP3 in the proliferating chondrocytes.
These data suggest that SOCS2 can inﬂuence hypertrophic
chondrocyte IGF-2 and IGFBP3 availability and thereby
modulate longitudinal bone growth.
The growth rate of tibia from ghr/Igf1 null mice are almost
identical to the sum of growth deﬁcit observed in the single ghr
and igf1r mutants suggesting that GH and IGF-1 have
independent roles in promoting linear growth (Lupu et al.,
2001). Local administration of GHþIGF-1 however failed to
have an additive effect in hypophysectomised animals (Isgaard
et al., 1986). In agreement with this, we show that in Socs2-/-
metatarsals, dual treatment with GH and IGF-1 does not
promote longitudinal growth beyond individual stimulation.
This suggests that GH is promoting linear growth through a
common pathway with IGF-1. It is however plausible that the
increase in IGF-2 levels observed in Socs2-/- metatarsals
observed in this study are competing with the exogenous
IGF-1. As IGF-1 exhibits a higher binding afﬁnity to the IGF-1R
than IGF-2 it is likely that the growth promoting effects of IGF-2
would be masked (Danielsen et al., 1990; Germainlee et al.,
1992; Oh et al., 1993a).
In the present study GH stimulation also causes signiﬁcant
increase in IGFBP3 levels although, like IGF-1, the source of this
IGFBP3 maybe both chondrocytes and/or the surrounding
perichondrium (Parker et al., 2007). The increase is more
apparent in Socs2-/- metatarsals, where growth is promoted.
IGFBP3 is produced in a number of tissues and is regulated
mainly by GH, but also to some degree by IGF-1 (Kiepe et al.,
2005). It is the principal carrier of IGFs in serum, where it
functions to control tissue IGF concentrations and reduce
bioavailability (Clemmons, 1998). Depending on incubation
time and dose, it can inhibit or potentiate the actions of IGFs
(Demellow and Baxter, 1988; Stewart et al., 1993; Bagi et al.,
1994). IGFBP3 may have pro-apoptotic functions on
chondrocytes, independent of IGFs, which is likely mediated
through its own cell surface bound receptor (Oh et al., 1993b;
Spagnoli et al., 2002). The complex relationship between IGF’s
and IGFBP3 make it difﬁcult to deduce what its role may be in
this system. As there appears to be a correlation between
increased IGFBP3 and increased growth in response toGH, it is
unlikely that the effects of IGFBP3 are inhibitory in this model.
In conclusion, using the murine metatarsal model, this study
underscores the critical role of SOCS2 in controlling GH
anabolic effects on linear bone growth. This study also provides
compelling evidence to support the notion that in the absence
of SOCS2, GH can regulate linear growth via local mechanisms
that are not accompanied by a rise in local or circulating IGF-1.
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